PARProceedings of Anticancer Research2208-35452208-3553Bio-Byword Scientific Publishing Pty. Ltd.10.26689/par.v8i5.7415ArticleExpression and Prognostic Potential of ESR1 in Breast Cancerhttps://artdesignp.com/journal/PAR/8/5/10.26689/par.v8i5.7415Muhammad Akram2024852024-09-25This study aims to explore the potential of ESR1 as a biomarker in breast cancer (BRCA) using bioinformatics analysis tools. The up-regulation of ESR1 expression in BRCA was investigated using UALCAN and GEPIA2, illustrating its role in BRCA progression. Furthermore, analyses based on various variables such as gender, age, race, and pathological stages of BRCA patients revealed a consistent up-regulation of ESR1, emphasizing its role in the development and progression of BRCA. Additionally, an analysis of ESR1 promoter methylation levels across various parameters revealed hypomethylation, affirming the inverse correlation between methylation and ESR1 expression. Prognostic analysis further indicated that overexpression of ESR1 is associated with poor overall survival, highlighting its potential as a prognostic biomarker in BRCA. Moreover, genetic mutation analysis using cBioPortal disclosed a minor role of ESR1 genetic mutations in BRCA, with only 2.5% of genetic alterations observed. The STRING and DAVID tools were utilized to conduct pathway enrichment analysis, revealing diverse biological functions of ESR1 and its 10 interconnected genes. Altogether, these results underscore the significance of understanding ESR1 up-regulation in BRCA and demonstrate its potential as a therapeutic, diagnostic, and prognostic biomarker.

Andre F, Mardis E, Salm M, et al., 2014, Prioritizing Targets for Precision Cancer Medicine. Ann Oncol, 25(12): 2295–2303. https://doi.org/10.1093/annonc/mdu478

Bray F, Laversanne M, Sung H, et al., 2024, Global Cancer Statistics 2022: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin, 74(3): 229–263. https://doi.org/10.3322/caac.21834

Anastasiadi Z, Lianos GD, Ignatiadou E, et al., 2017, Breast Cancer in Young Women: An Overview. Updates Surg, 69(3): 313–317. https://doi.org/10.1007/s13304-017-0424-1

Smolarz B, Nowak AZ, Romanowicz H, 2022, Breast Cancer-Epidemiology, Classification, Pathogenesis and Treatment (Review of Literature). Cancers (Basel), 14(10): 2569. https://doi.org/10.3390/cancers14102569

Bellanger M, Zeinomar N, Tehranifar P, et al., 2018, Are Global Breast Cancer Incidence and Mortality Patterns Related to Country-Specific Economic Development and Prevention Strategies? J Glob Oncol, 4: 1–16. https://doi.org/10.1200/JGO.17.00207

Ataollahi MR, Sharifi J, Paknahad MR, et al., 2015, Breast Cancer and Associated Factors: A Review. J Med Life, 8(Spec Iss 4): 6–11.

Weigelt B, Horlings HM, Kreike B, et al., 2008, Refinement of Breast Cancer Classification by Molecular Characterization of Histological Special Types. J Pathol, 216(2): 141–150. https://doi.org/10.1002/path.2407

Joshi H, Press MF, 2018, 22—Molecular Oncology of Breast Cancer, in: Bland KI, Copeland EM, Klimberg VS, et al. (eds), The Breast (5th ed). Elsevier, Amsterdam, 282–307.e5.

Perou CM, Sørlie T, Eisen MB, et al., 2000, Molecular Portraits of Human Breast Tumours. Nature, 406(6797): 747–752. https://doi.org/10.1038/35021093

Burguin A, Diorio C, Durocher F, 2021, Breast Cancer Treatments: Updates and New Challenges. J Pers Med, 11(8): 808. https://doi.org/10.3390/jpm11080808

Pisani P, Bray F, Parkin DM, 2002, Estimates of the World-Wide Prevalence of Cancer for 25 Sites in the Adult Population. Int J Cancer, 97(1): 72–81. https://doi.org/10.1002/ijc.1571

NIH National Cancer Institute: Surveillance, Epidemiology, and End Results Program, Cancer Stat Facts: Female Breast Cancer Subtypes, viewed January 3, 2024, https://seer.cancer.gov/statfacts/html/breast-subtypes.html

Bergin ART, Loi S, 2019, Triple-Negative Breast Cancer: Recent Treatment Advances. F1000Res, 8: F1000 Faculty Rev-1342. https://doi.org/10.12688/f1000research.18888.1

Nishimura R, Osako T, Okumura Y, et al., 2010, Ki-67 as A Prognostic Marker According to Breast Cancer Subtype and A Predictor of Recurrence Time in Primary Breast Cancer. Exp Ther Med, 1(5): 747-754. https://doi.org/10.3892/etm.2010.133

Sotiriou C, Neo SY, McShane LM, et al., 2003, Breast Cancer Classification and Prognosis Based on Gene Expression Profiles from A Population-Based Study. Proc Natl Acad Sci U S A, 100(18): 10393–10398. https://doi.org/10.1073/pnas.1732912100

Hu Z, Fan C, Oh DS, et al., 2006, The Molecular Portraits of Breast Tumors are Conserved Across Microarray Platforms. BMC Genomics, 7: 96. https://doi.org/10.1186/1471-2164-7-96

Yersal O, Barutca S, 2014, Biological Subtypes of Breast Cancer: Prognostic and Therapeutic Implications. World J Clin Oncol, 5(3): 412–424. https://doi.org/10.5306/wjco.v5.i3.412

Maass H, Jonat W, Stolzenbach G, et al., 1980, The Problem of Nonresponding Estrogen Receptor-Positive Patients with Advanced Breast Cancer. Cancer, 46(12 Suppl): 2835–2837. https://doi.org/10.1002/1097-0142(19801215)46:12+3.0.co;2-m

Osborne CK, Schiff R, 2011, Mechanisms of Endocrine Resistance in Breast Cancer. Annu Rev Med, 62: 233–247. https://doi.org/10.1146/annurev-med-070909-182917

Olefsky JM, 2001, Nuclear Receptor Minireview Series. J Biol Chem, 276(40): 36863–36864. https://doi.org/10.1074/jbc.R100047200

Lupien M, Meyer CA, Bailey ST, et al., 2010, Growth Factor Stimulation Induces A Distinct ER(alpha) Cistrome Underlying Breast Cancer Endocrine Resistance. Genes Dev, 24(19): 2219–2227. https://doi.org/10.1101/gad.1944810

Klinge CM, 2001, Estrogen Receptor Interaction with Estrogen Response Elements. Nucleic Acids Res, 29(14): 2905–2919. https://doi.org/10.1093/nar/29.14.2905

Kushner PJ, Agard DA, Greene GL, et al., 2000, Estrogen Receptor Pathways to AP-1. J Steroid Biochem Mol Biol, 74(5): 311–317. https://doi.org/10.1016/s0960-0760(00)00108-4

Fribbens C, Garcia Murillas I, Beaney M, et al., 2018, Tracking Evolution of Aromatase Inhibitor Resistance with Circulating Tumour DNA Analysis in Metastatic Breast Cancer. Ann Oncol, 29(1): 145–153. https://doi.org/10.1093/annonc/mdx483

Chandrashekar DS, Bashel B, Balasubramanya SAH, et al., 2017, UALCAN: A Portal for Facilitating Tumor Subgroup Gene Expression and Survival Analyses. Neoplasia, 19(8): 649–658. https://doi.org/10.1016/j.neo.2017.05.002

Lanczky A, Gyorffy B, 2021, Web-Based Survival Analysis Tool Tailored for Medical Research (KMplot): Development and Implementation. J Med Internet Res, 23(7): e27633. https://doi.org/10.2196/27633

Tang Z, Kang B, Li C, et al., 2019, GEPIA2: An Enhanced Web Server for Large-Scale Expression Profiling and Interactive Analysis. Nucleic Acids Res, 47(W1): W556–W560. https://doi.org/10.1093/nar/gkz430

Cerami E, Gao J, Dogrusoz U, et al., 2012, The cBio Cancer Genomics Portal: An Open Platform for Exploring Multidimensional Cancer Genomics Data. Cancer Discov, 2(5): 401–404. https://doi.org/10.1158/2159-8290.CD-12-0095. Erratum in Cancer Discov, 2(10): 960.

Szklarczyk D, Franceschini A, Wyder S, et al., 2015, STRING v10: Protein-Protein Interaction Networks, Integrated Over the Tree of Life. Nucleic Acids Res, 43(Database issue): D447–D452. https://doi.org/10.1093/nar/gku1003

Sherman BT, Hao M, Qiu J, et al., 2022, DAVID: A Web Server for Functional Enrichment Analysis and Functional Annotation of Gene Lists (2021 Update). Nucleic Acids Res, 50(W1): W216–W221. https://doi.org/10.1093/nar/gkac194

Asakawa M, Itoh M, Suganami T, et al., 2019, Upregulation of Cancer-Associated Gene Expression in Activated Fibroblasts in A Mouse Model of Non-Alcoholic Steatohepatitis. Sci Rep, 9(1): 19601. https://doi.org/10.1038/s41598-019-56039-0

Li M, Sun Q, Wang X, 2017, Transcriptional Landscape of Human Cancers. Oncotarget, 8(21): 34534–34551. https://doi.org/10.18632/oncotarget.15837

Luczak MW, Jagodzinski PP, 2006, The Role of DNA Methylation in Cancer Development. Folia Histochem Cytobiol, 44(3): 143–154.

Sweet-Cordero EA, Biegel JA, 2019, The Genomic Landscape of Pediatric Cancers: Implications for Diagnosis and Treatment. Science, 363(6432): 1170–1175. https://doi.org/10.1126/science.aaw3535

Li Y, Zhang H, Merkher Y, et al., 2022, Recent Advances in Therapeutic Strategies for Triple-Negative Breast Cancer. J Hematol Oncol, 15: 121. https://doi.org/10.1186/s13045-022-01341-0

Polverini PJ, 2002, Angiogenesis in Health and Disease: Insights into Basic Mechanisms and Therapeutic Opportunities. J Dent Educ, 66(8): 962–975.

Armstrong N, Ryder S, Forbes C, et al., 2019, A Systematic Review of the International Prevalence of BRCA Mutation in Breast Cancer. Clin Epidemiol, 11: 543–561. https://doi.org/10.2147/CLEP.S206949

Abu-Helalah M, Azab B, Mubaidin R, et al., 2020, BRCA1 and BRCA2 Genes Mutations Among High Risk Breast Cancer Patients in Jordan. Sci Rep, 10(1): 17573. https://doi.org/10.1038/s41598-020-74250-2

Obeagu EI, Obeagu GU, 2024, Breast Cancer: A Review of Risk Factors and Diagnosis. Medicine (Baltimore), 103(3): e36905. https://doi.org/10.1097/MD.0000000000036905

Nagel A, Szade J, Iliszko M, et al., 2019, Clinical and Biological Significance of ESR1 Gene Alteration and Estrogen Receptors Isoforms Expression in Breast Cancer Patients. Int J Mol Sci, 20(8): 1881. https://doi.org/10.3390/ijms20081881

Reinert T, Saad ED, Barrios CH, et al., 2017, Clinical Implications of ESR1 Mutations in Hormone Receptor-Positive Advanced Breast Cancer. Front Oncol, 7: 26. https://doi.org/10.3389/fonc.2017.00026